Also, lipase inhibitors (Padjusted = 6.08 × 10−3) and the statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) pathway (Padjusted = 3.99 × 10−2) were significantly enriched for AD and GERD (Supplementary Data 27), suggesting mechanisms of these medications may find therapeutic application in AD and GIT disorders. This evidence concerns the gene HMGCR and Alzheimer disease.